<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="795">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04418206</url>
  </required_header>
  <id_info>
    <org_study_id>20-PP-10</org_study_id>
    <nct_id>NCT04418206</nct_id>
  </id_info>
  <brief_title>Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19</brief_title>
  <acronym>EliSpot</acronym>
  <official_title>Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RT-PCR on rhino-pharynge sampling highlights the genetic material of the virus and
      indicates that a subject is infected with SARS-CoV-2. This test can be in about 30% of false
      negative cases, it does not allow to date the infection, nor to predict the asymptomatic,
      mild, moderate or severe evolution of the disease. In terms of public health, we need 1/ to
      better understand the chronology of the immune response to the virus in the general
      population and in contacts of index cases; 2/ To know which characteristics of the immune
      response are protective of future reinfections. Finally, in symptomatic subjects, we need
      biomarkers that predict the evolutionary mode of the disease (moderate vs. severe form).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>COVID-19 patients will be selected in the 4 participating centres Contact subjects and healthy volunteers will be selected only in the coordinating centre (Centre Hospitalier Universitaire de Nice)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IgA specific cells of SARS</measure>
    <time_frame>At 7 days</time_frame>
    <description>Proportion of subjects with IgA-specific cells of SARS-CoV-2's Spike 1 protein at inclusion and 7 +/-2 days later</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OMS progression scale</measure>
    <time_frame>At 7 days</time_frame>
    <description>The scale is 7-point ordinal.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Covid 19</condition>
  <arm_group>
    <arm_group_label>Samples With DNA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nasopharyngal swab and blood samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patients COVID 19</intervention_name>
    <description>Exposure to SARS-Cov2 but no symptoms (patient's family, medical staff) and General population (volunteers not exposed to SARS-Cov2)</description>
    <arm_group_label>Samples With DNA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age â‰¥ 18 years,

          -  patients with confirmed SARS-Cov2 infection (RT PCR positive)

          -  or patients suspected (evocative chest scanner)

          -  OR patients exposure to SARS-CoV2 but no symptoms (patient's family, caregivers)

          -  OR patients Non exposure to SARS-Cov2 volunteer subjects (general population)

        Exclusion Criteria:

          -  pregnant or breastfeeding female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LEROY Sylvie</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nice, pneumologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leroy Sylvie</last_name>
    <phone>+33492038580</phone>
    <email>ARCSpneumologie@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>griffonnet Jennifer</last_name>
    <phone>+33492038580</phone>
    <email>ARCSpneumologie@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Antibes</name>
      <address>
        <city>Antibes</city>
        <state>Alpes Maritimes</state>
        <zip>06606</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>LEROUSSEAU LIONEL</last_name>
      <phone>+334 97 24 76 06</phone>
      <email>l.lerousseau@ch-antibes.fr</email>
    </contact>
    <investigator>
      <last_name>lerousseau lionel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Cannes, Pneumologie</name>
      <address>
        <city>Cannes</city>
        <state>Alpes Maritimes</state>
        <zip>06414</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Rolland Fabien</last_name>
      <phone>+334 92 18 20 58</phone>
      <email>f.rolland@ch-cannes.fr</email>
    </contact>
    <investigator>
      <last_name>rolland Fabien</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Grasse</name>
      <address>
        <city>Grasse</city>
        <state>Alpes Maritimes</state>
        <zip>06355</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>DUMON MARIE CHRISTINE</last_name>
      <phone>+33492095555</phone>
      <email>mc.dumon@ch-grasse.fr</email>
    </contact>
    <investigator>
      <last_name>DUMON MARIE CHRISTINE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de nice</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>LEROY SYLVIE</last_name>
      <phone>+33492038580</phone>
      <email>ARCSpneumologie@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>LEROY SYLVIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

